ATHA (Athira Pharma) Float Percentage Of Total Shares Outstanding : 70.81% (As of Mar. 22, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Athira Pharma's float shares is 27.64 Mil. Athira Pharma's total shares outstanding is 39.04 Mil. Athira Pharma's float percentage of total shares outstanding is 70.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Athira Pharma's Insider Ownership is 6.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Athira Pharma's Institutional Ownership is 46.40%.

Athira Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Athira Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	27.64	/	39.04
	=	70.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Athira Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011

Website

https://www.athira.com

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Executives

Mark James Litton	officer: Chief Operating Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington	officer: General Counsel	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Kevin Church	officer: Vice President of Discovery	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Rachel Lenington	officer: Chief Technology Officer	C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Andrew Gengos	officer: See Below	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Kelly A Romano	director	C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Grant Pickering	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Glenna Mileson	officer: Chief Financial Officer	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Hans Moebius	officer: Chief Medical Officer	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara	director	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz	director	3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014